Compare HTH & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTH | SUPN |
|---|---|---|
| Founded | 1998 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.9B |
| IPO Year | 2004 | 2012 |
| Metric | HTH | SUPN |
|---|---|---|
| Price | $33.83 | $49.23 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $34.00 | ★ $61.60 |
| AVG Volume (30 Days) | 353.0K | ★ 602.1K |
| Earning Date | 01-29-2026 | 02-24-2026 |
| Dividend Yield | ★ 2.12% | N/A |
| EPS Growth | ★ 53.28 | N/A |
| EPS | ★ 2.50 | N/A |
| Revenue | ★ $1,259,399,000.00 | $681,539,000.00 |
| Revenue This Year | N/A | $8.32 |
| Revenue Next Year | $1.64 | $23.36 |
| P/E Ratio | $13.57 | ★ N/A |
| Revenue Growth | ★ 7.66 | 4.54 |
| 52 Week Low | $26.67 | $29.16 |
| 52 Week High | $36.14 | $57.65 |
| Indicator | HTH | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 41.80 | 52.86 |
| Support Level | $34.27 | $51.01 |
| Resistance Level | $35.37 | $52.30 |
| Average True Range (ATR) | 0.49 | 1.38 |
| MACD | -0.17 | 0.05 |
| Stochastic Oscillator | 18.96 | 49.85 |
Hilltop Holdings Inc is a Dallas-based financial holding company. The Company has two primary business units, PCC (banking and mortgage origination) and Securities Holdings (broker-dealer). The banking segment includes the operations of the Bank. The banking segment provides business and consumer banking services from offices located throughout Texas and generates revenue from its portfolio of earning assets. The broker-dealer segment includes the operations of Securities Holdings, which operates through its wholly owned subsidiaries Hilltop Securities, Asset Managment LLC, etc. The broker-dealer segment generates a majority of its revenues from fees and commissions earned from investment advisory and securities brokerage services. Majority of revenue is from Banking Segment.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.